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sion analysis.  Results: The most common symptom was 
tiredness ( n = 1,002; 82.1%), followed by dyspnea ( n = 845; 
69.3%), appetite loss ( n = 801; 65.7%), pain ( n = 798; 65.4%), 
drowsiness ( n = 742; 60.8%), anxiety ( n = 704; 57.7%), depres-
sion ( n = 623; 51.1%), and nausea ( n = 557; 45.5%). Of the 
1,245 patients, 590 (48.4%) had difficulty in initiating or 
maintaining sleep. The symptoms were more severe in stag-
es III and IV. Logistic regression analysis indicated a clear as-
sociation between demographic characteristics and symp-
tom distress, as well as between symptom distress (except 
nausea) and well-being. Overall, 804 (65.4%) patients used 
analgesics, 630 (51.5%) received treatment for dyspnea, 242 
(19.8%) used enteral/parenteral nutrition, 132 (10.8%) used 
appetite stimulants, and 129 (10.6%) used anxiolytics/anti-
depressants. Of the 799 patients who received analgesics, 
173 (21.7%) reported that their symptoms were under con-
trol, and also those on other various treatment modalities 
 Keywords 
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Treatment 
 Abstract 
 Objective: To investigate the symptoms of lung cancer in 
Turkey and to evaluate approaches to alleviate these symp-
toms.  Subjects and Methods: This study included 1,245 lung 
cancer patients from 26 centers in Turkey. Demographic 
characteristics as well as information regarding the disease 
and treatments were obtained from medical records and pa-
tient interviews. Symptoms were evaluated using the Ed-
monton Symptom Assessment Scale (ESAS) and were grad-
ed on a scale between 0 and 10 points. Data were compared 
using the χ 2 , Student  t, and Mann-Whitney U tests. Potential 
predictors of symptoms were analyzed using logistic regres-
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(dyspnea: 78/627 [12.4%], appetite stimulant: 25/132 
[18.9%], and anxiolytics/antidepressants: 25/129 [19.4%]) re-
ported that their symptoms were controlled.  Conclusion: In 
this study, the symptoms progressed and became more se-
vere in the advanced stages of lung cancer, and palliative 
treatment was insufficient in most of the patients in Turkey. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 Lung cancer is a highly mortal disease with poor sur-
vival rates. Patients with lung cancer suffer many limita-
tions due to symptoms related to the disease and its treat-
ment  [1] . Most patients with lung cancer are symptom-
atic at presentation, and most of them experience multiple 
symptoms, including dyspnea, pain, fatigue, anorexia, 
nausea, anxiety, and depression, especially in the ad-
vanced stages  [1] .
 Lung cancer symptoms are known to cause secondary 
effects on the emotional, social, physical, and spiritual 
well-being of patients  [2] . Because there is a close rela-
tionship between the symptoms, quality of life, and sur-
vival, early implementation of palliative care has been re-
ported to improve a patient’s quality of life, symptom 
burden, and even survival  [3] . However, in clinical prac-
tice, the importance of symptoms and palliative care is 
often neglected by physicians, and is generally not con-
sidered in the disease’s management  [4] .
 The goal of palliative care is to provide relief from pain 
and other distressing symptoms in order to give patients 
and their families the best possible quality of life, regard-
less of disease stage or need for other therapies  [5] . Com-
mon pulmonary symptoms of lung cancer that require 
palliative therapy include those caused by the cancer it-
self, i.e., dyspnea, wheezing, cough, hemoptysis, and chest 
pain; locoregional metastases within the thorax, i.e., su-
perior vena cava syndrome, pleural effusions, etc.; or by 
distant metastases, i.e., bone and brain  [1] . Hence, this 
study, which was conducted in Turkey, aimed to investi-
gate the symptoms of lung cancer and its treatment, as 
well as to evaluate approaches for palliating those symp-
toms.
 Subjects and Methods 
 Following approval from the Ethics Committee of Karadeniz 
Technical University Faculty of Medicine, this multicenter and 
prospective study was performed at 26 centers in Turkey from 
March 2014 to September 2014. During the study period, all lung 
cancer patients (both old and newly diagnosed for any stage) who 
presented at the hospital were included in the study if they agreed 
to participate and signed informed consent.
 Demographic characteristics and disease and treatment vari-
ables were collected for each patient by physicians using a stan-
dard questionnaire, which was completed during face-to-face 
interviews, and hospital records. The symptoms at the time of 
data collection were recorded and graded using the Edmonton 
Symptom Assessment Scale (ESAS). The ESAS symptom scores 
were categorized by severity as follows: none = 0; mild = 1–3; 
moderate = 4–6; and severe = 7–10. The ESAS is a patient-report-
ed validated tool for assessment of symptoms and its validity and 
reliability of ESAS for use in a Turkish population were estab-
lished by Yesilbalkan et al.  [3, 6] . The ESAS was supplemented 
with a question regarding whether or not the patient had diffi-
culty initiating or maintaining sleep: “Do you frequently have 
difficulty in falling asleep at night or waking up frequently dur-
ing the night or getting back to sleep after waking during the 
night?”
 Data analysis (regarding the demographic characteristics, 
symptoms, and the potential predictors of symptoms) were per-
formed using SPSS software (Version 13.01; SPSS Inc., Chicago, 
IL, USA). The χ 2 test was used to compare categorical variables. 
The parametric Student  t test was used for comparing mean or 
median values of normally distributed data, and the nonparamet-
 Table 1.  Characteristics of disease and treatment options in pa-
tients with lung cancer
n (%)
Histopathologic diagnosis (n = 1,245)
Squamous cell carcinoma 489 (39.3)
Adenocarcinoma 369 (29.6)
Small-cell lung carcinoma 237 (19.0)
NSCLC-not otherwise specified 127 (10.2)
Others 23 (1.8)
Stage of disease (n = 1,202)
Stage I 78 (6.5)
Stage II 121 (10.1)
Stage III 332 (27.6)
Stage IV 671 (55.8)
Metastases
Bones (n = 663) 291 (43.9)
Brain (n = 667) 154 (23.1)
Liver (n = 665) 134 (20.2)
Adrenal glands (n = 664) 116 (17.5)
Other (n = 718) 151 (20.0)





 1 First-line treatment options that have been delivered or are 
currently being delivered.
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ric Mann-Whitney U test was used to compare data that was not 
normally distributed. Factors that were potential predictors of 
symptoms (age, gender, body weight, disease stage, comorbidities, 
weight loss, histology [small-/non-small-cell lung cancer], metas-
tasis, and time since diagnosis) were analyzed using logistic regres-
sion, as were symptoms that were the potential predictors of lack 
of well-being (pain, tiredness, drowsiness, nausea, lack of appetite, 
shortness of breath, depression, and anxiety). Multivariate logistic 
regression analysis was used as a stepwise descending method 
from predictive factors with a significance  ≤ 0.05 in the univariate 
analysis.
 Results 
 A total of 1,245 lung cancer patients (1,104 [88.7%] 
males; 141 [11.3%] females) participated in the study. 
However, the number of patients included in analyses 
was variable because of some missing data. Of the 1,202 
patients, 671 (55.8%) had stage IV disease and the most 
frequent histologic type was squamous cell cancer ( Ta-
ble 1 ). The mean age of the patients was 61.8 ± 9.4 years. 
The ESAS revealed that 1,085/1,216 (89.2%) of the pa-
tients had more than one symptom, and tiredness 
1,002/1,220 (82.1%) was the most common symptom. 
There was a gradual increase in severity of symptoms 
based on the disease stages ( Table 2 ). Patients with stages 
III and IV disease had more symptoms, and those with 
earlier stages had higher levels of well-being ( Table 2 ). Of 
the patients, 590/1,218 (48.4%) had difficulty initiating or 
maintaining sleep, and this was more common in the ad-
vanced stages (509/980 [51.9%] vs. 63/200 [31.5%],  p < 
0.0001). Six hundred eleven (49.3%) patients had unin-
tended weight loss of at least 5 kg, while 164 (13.2%) pa-
tients gained weight during the treatment period. Weight 
loss was also more significant in the advanced stages 
(517/1,002 [51.6%] vs. 75/199 [37.7%],  p < 0.001).
 Logistic regression analysis indicated a clear associa-
tion between demographic characteristics (age, gender, 
comorbidities, body weight, weight loss, disease stage, 
metastasis, and time since diagnosis) and symptom dis-
tress ( Table 3 ). There was also a significant association 
between the symptom distress (except nausea) and well-
being ( Table 4 ).
 Palliation of Symptoms 
 Dyspnea 
 Overall, 51.5% of the patients (630/1,223) received 
treatment for dyspnea ( Table  5 ). Of the 1,223 patients 
who received treatment for dyspnea, 78 (12.4%) had reso-
lution of dyspnea; while the remaining 549 (87.6%) did 
not. On the other hand, 256 patients with mild/moderate 
dyspnea and 37 with severe dyspnea (total 293: 34.8%) 
received no palliative therapy for their dyspnea.
 Table 2.  Distribution of symptoms according to severity and disease stage in patients with lung cancer









Pain 1 – 2 79 (39.7) 68 (34.2) 31 (15.6) 21 (10.6) 1,186 <0.0001
3 – 4 327 (33.1) 246 (24.9) 216 (21.9) 198 (20.1)
Tiredness 1 – 2 48 (24.1) 69 (34.7) 51 (25.6) 31 (15.6) 1,186 <0.0001
3 – 4 166 (16.8) 201 (20.4) 252 (25.5) 368 (37.3)
Drowsiness 1 – 2 90 (45.2) 66 (33.2) 26 (13.1) 17 (8.5) 1,187 <0.0001
3 – 4 375 (38.0) 242 (24.5) 162 (14.6) 209 (21.2)
Nausea 1 – 2 115 (57.5) 48 (24.0) 30 (15.0) 7 (3.5) 1,189 0.018
3 – 4 529 (53.5) 210 (21.2) 145 (14.7) 105 (10.6)
Lack of appetite 1 – 2 95 (47.0) 50 (24.8) 38 (18.8) 19 (9.4) 1,191 <0.0001
3 – 4 319 (32.3) 177 (17.9) 199 (20.1) 294 (29.7)
Shortness of breath 1 – 2 51 (25.6) 78 (39.2) 48 (24.1) 22 (11.1) 1,185 <0.0001
3 – 4 313 (31.7) 231 (23.4) 202 (20.5) 240 (24.3)
Depression 1 – 2 112 (56.3) 55 (27.6) 16 (8.0) 16 (8.0) 1,185 <0.0001
3 – 4 468 (47.5) 200 (20.3) 163 (16.5) 155 (15.7)
Anxiety 1 – 2 98 (49.2) 55 (27.6) 26 (13.1) 20 (10.1) 1,186 0.002
3 – 4 404 (40.9) 218 (22.1) 170 (17.2) 195 (19.8)
Well-being 1 – 2 71 (45.3) 63 (37.3) 39 (6.7) 25 (10.7) 1,185 <0.0001
3 – 4 261 (38.6) 219 (21.9) 251 (25.9) 256 (13.6)




 Overall, of 1,229 patients, 804 (65.4%) used analgesics 
( Table 5 ). Nonnarcotic and narcotic analgesic use alone 
or in combined forms were detected in 693 (86.2%) and 
320 (39.8%) patients using analgesics ( n = 804), respec-
tively. Among the entire study population, these rates 
were 56.4% (693/1,229) and 26.0% (320/1,229), respec-
tively. Only 173 (21.7%) of the patients receiving analge-
sics reported complete pain relief; 626 (78.3%) patients 
reported continuing pain despite analgesic use. In con-
trast, 171 (21.5%) patients reported no analgesic use de-
spite having pain (147 with mild/moderate pain, 24 with 
severe pain). Two hundred ninety-one (43.9%) patients 
had metastases to bone, and of these only 135 (39.6%) 
were treated with bisphosphonates and 88 (30.2%) were 
treated with palliative radiation.
Variables1 OR 95% CI p
Pain
Gender (female) 1.402 0.929 – 2.115 0.107
Body weight 0.987 0.977 – 0.996 0.007
Disease stage 0.944 0.735 – 1.213 0.653
Weight loss 1.023 1.007 – 1.040 0.005
Metastasis 1.727 1.102 – 2.708 0.017
TST 0.986 0.977 – 0.994 0.001
Tiredness
Body weight 0.982 0.971 – 0.993 0.002
Disease stage 1.130 0.861 – 1.484 0.378
Weight loss 1.031 1.002 – 1.060 0.037
Metastasis 1.537 0.914 – 2.587 0.105
Drowsiness
Age 1.010 0.996 – 1.024 0.152
Body weight 0.997 0.987 – 1.006 0.524
Disease stage 1.032 0.803 – 1.326 0.807
Comorbidity 1.264 0.979 – 1.632 0.072
Weight loss 1.044 1.021 – 1.067 <0.0001
Metastasis 1.640 1.048 – 2.567 0.031
TST 0.990 0.987 – 0.998 0.020
Nausea
Age 0.985 0.972 – 0.997 0.017
Body weight 0.991 0.982 – 1.000 0.057
Disease stage 1.020 0.790 – 1.317 0.881
Weight loss 1.030 1.011 – 1.050 0.002
Metastasis 1.276 0.814 – 2.001 0.289
TST 0.986 0.977 – 0.995 0.004
Lack of appetite
Age 1.008 0.993 – 1.022 0.314
Body weight 0.970 0.960 – 0.980 <0.001
Disease stage 1.172 0.903 – 1.520 0.234
Comorbidity 1.463 1.114 – 1.921 0.006
Weight loss 1.046 1.022 – 1.072 <0.001
Metastasis 1.477 0.924 – 2.361 0.103
TST 0.987 0.972 – 0.991 <0.001
Variables1 OR 95% CI p
Shortness of breath
Age 1.005 0.991 – 1.019 0.502
Body weight 0.984 0.975 – 0.993 0.001
Comorbidity 1.903 1.462 – 2.477 <0.001
Depression
Gender (female) 1.777 1.210 – 2.610 0.003
Body weight 0.988 0.979 – 0.997 0.010
Disease stage 1.065 0.826 – 1.374 0.626
Comorbidity 1.421 1.116 – 1.809 0.004
Weight loss 1.042 1.021 – 1.063 <0.0001
Metastasis 1.353 0.863 – 2.119 0.187
TST 0.988 0.979 – 0.997 0.009
Anxiety
Age 1.010 0.996 – 1.023 0.167
Gender (female) 1.791 1.195 – 2.684 0.005
Body weight 0.991 0.982 – 1.001 0.071
Disease stage 1.088 0.846 – 1.401 0.511
Comorbidity 1.238 0.961 – 1.594 0.098
Weight loss 1.040 1.018 – 1.062 <0.0001
Metastasis 1.328 0.848 – 2.079 0.215
TST 0.992 0.983 – 1.001 0.077
Poor well-being
Age 1.028 1.013 – 1044 <0.0001
Body weight 0.981 0.971 – 0.991 <0.0001
Disease stage 0.998 0.770 – 1.294 0.990
Comorbidity 1.198 0.903 – 1.590 0.211
Weight loss 1.049 1.022 – 1.077 <0.0001
Metastasis 2.168 1.349 – 3.484 0.001
TST 0.991 0.982 – 1.000 0.044
Awakening
Gender (female) 1.361 0.936 – 1.979 0.107
Disease stage 1.403 1.080 – 1.822 0.011
Comorbidity 1.406 1.107 – 1.785 0.005
Weight loss 1.027 1.008 – 1.046 0.004
Metastasis 1.291 0.822 – 2.027 0.267
 Table 3.  Multivariate logistic regression analysis of demographic parameters predicting symptoms in lung cancer
 TST, time since diagnosis. 1 Only variables derived from predictive factors with a significance ≤0.05 in the univariate analysis were 
included.
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 Enteral/Parenteral Nutrition, Appetite Stimulant, and 
Vitamin Use 
 Two hundred forty-two patients (out of 1,222; 19.8%) 
received enteral or parenteral nutrition; this was more 
prevalent in advanced stages than in those with stages I 
and II (21.4 vs. 10.0%, respectively,  p < 0.001). The rea-
sons that patients used nutritional products were diffi-
culty swallowing (35/221, 15.8%), cachexia (85/221, 
38.5%), and other causes (101/221, 45.7%). The nutri-
tional support was given via an oral route in 192/239 pa-
tients (80.3%), via nasogastric tube in 10/239 patients 
(4.2%), via percutaneous endoscopic gastrostomy in 
2/239 patients (0.8%), and via parenteral route in 35/239 
patients (14.6%).
 Of 1,224 patients, 132 (10.8%) were using appetite 
stimulants, and use was more frequent in patients at ad-
vanced stages (12.3 vs. 4.5%,  p < 0.001). Of these, 93 
(70.4%) used megestrol acetate, 29 (22.0%) used cypro-
heptadine, 2 (5.4%) used a combination of these drugs, 
and 8 (6.1%) used other medications. Overall, 81/1,041 
(6.6%) reported vitamin use, and 238/1,227 patients 
(19.4%) reported the use of blood products including 
whole blood, erythrocyte suspension, plasma, etc.
 Of the patients with appetite loss, 107/792 (13.4%) 
were using appetite stimulants (79 megestrol acetate, 21 
cyproheptadine, 9 a combination of drugs, and 5 other 
drugs). Twenty-five patients (18.9%) using an appetite 
stimulant reported no appetite loss. Similarly, 77/602 
(12.8%) of the patients with weight loss were using an 
appetite stimulant (55 megestrol acetate, 17 cyprohepta-
dine, 1 combination, 2 other). Again 38/454 (8.4%) of 
the patients with no weight loss and 17/163 (10.4%) of 
the patients with weight gain were using appetite stimu-
lants.
 Anxiolytic/Antidepressant Drugs and Sleeping Pills 
 One hundred twenty-nine patients (129/1,222, 10.6%) 
received anxiolytic/antidepressant treatment. Of these 
patients, 104 (80.6%) had only depression or anxiety, 
while 25 (19.4%) did not report having depression or anx-
iety. One hundred four patients (104/1,221, 8.5%) used 
sleeping pills and 84 of these patients (80.8%) had com-
plained of difficulty with sleep.
 Discussion 
 In the current study, more than 85% of the lung can-
cer patients experienced multiple symptoms (ranging 
from mild to severe) regardless of their disease stage. 
Symptoms were more severe in the advanced stages than 
in stages I–II of the disease; the most common symptom 
was tiredness, followed by shortness of breath, loss of 
appetite, pain, drowsiness, anxiety, depression, and nau-
sea. The finding that tiredness was the most common 
symptom of lung cancer was consistent with previous 
studies  [4, 7] . Equally, the findings that age, gender, co-
morbidities, body weight, weight loss, disease stage, me-
 Table 4.  Multivariate logistic regression analysis of symptoms pre-
dicting well-being in patients with lung cancer
Symptoms  Poor well-being p
OR  95% CI
Pain 2.287 1.619 – 3.231 <0.0001
Tiredness 1.738 1.141 – 2.648 0.010
Drowsiness 2.020 1.419 – 2.875 <0.0001
Nausea 0.975 0.646 – 1.472 0.905
Lack of appetite 3.675 2.543 – 5.312 <0.0001
Shortness of breath 1.842 1.293 – 2.624 0.001
Depression 2.848 1.723 – 4.708 <0.0001
Anxiety 4.281 2.717 – 6.745 <0.0001







Treatment of dyspnea (51.5%, 630/1,223)
Bronchodilator 562/624 (90.1) 562/1217 (46.2)
Home oxygen 177/619 (28.6) 177/1212 (14.6)
Nebulizer 175/617 (28.4) 175/1210 (14.5)
Palliative radiotherapy 55/613 (9.0) 55/1206 (4.6)
Thoracentesis 43/613 (7.0) 43/1206 (3.6)
NIMV 18/610 (2.9) 18/1210 (1.5)
Endobronchial treatment/
stenting 12/614 (2.0) 12/1207 (1.0)
Pleurodesis 11/613 (1.8) 11/1206 (1.0)
Analgesic use (65.4%, 804/1,229)
Paracetamol/ NSAID 476/804 (59.2) 476/1224 (38.9)
Tramadol 46/804 (5.7) 46/1215 (3.8)
Fentanyl 36/804 (4.5) 36/1214 (2.9)
Morphine 3/804 (0.4) 3/1211 (0.2
NSAIDs+tramadol 73/804 (9.1) 73/1212 (6.0)
NSAIDs+fentanyl 59/804 (7.3) 59/1211 (4.9)
NSAIDs+tramadol+fentanyl 46/804 (5.7) 46/1211 (3.8)
Other combinations 62/804 (7.7) 62/1211 (5.2)
 NIMV, noninvasive mechanical ventilation; NSAID, nonste-
roidal anti-inflammatory drug.
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tastasis, and time since diagnosis were independent pre-
dictors of lung cancer symptoms are similar to demo-
graphic features including age, gender, disease stage, 
treatment type, comorbidities, income, and weight loss 
that had been reported to be associated with symptom 
distress  [8–10] .
 The finding in the current study that symptom distress 
was an independent predictor of well-being, except for 
nausea, was consistent with that of Lien et al.  [11] , who 
reported that the number of symptoms was negatively 
correlated with emotional distress and sense of well-be-
ing. Anxiety was the symptom that was most significant-
ly associated with poor well-being. Smalbrugge et al. [12] 
also showed that presence of depression and/or anxiety 
has a clinically significant negative impact on well-being.
 Our results indicate that there are a significant number 
of unmet needs reported by patients with lung cancer. 
Most patients in our study reported continuing symp-
toms, and a significant number of patients with dyspnea 
and pain reported that they were not receiving treatment. 
Similar to our results, some studies reported that lung can-
cer patients with high symptom scores were not undergo-
ing any treatment  [7, 9] . Several studies have also shown 
that there is a high prevalence of uncontrolled symptoms 
in patients with advanced lung cancer  [7, 13, 14] .
 Dyspnea is common in patients with lung cancer; it 
may develop due to malignant airway obstruction, lym-
phangitic spread, radiation or drug-induced pneumoni-
tis, pleural effusion, accompanying chronic obstructive 
pulmonary disease, etc. Patient discomfort may be allevi-
ated by radiotherapy, endobronchial treatment/stent 
placement, and thoracentesis, or pleurodesis for pleural 
effusion. In the present study, the rates of palliative radio-
therapy, thoracentesis, endobronchial treatment/stent 
placement, and pleurodesis were 4.6, 3.6, 1.0, and 1.0%, 
respectively; these results were comparable to those of the 
LUCEOR study  [5] . However, home oxygen use and 
bronchodilator use in the current study were higher; we 
believe that those high percentages reflect the rate of co-
morbid chronic obstructive pulmonary disease patients, 
since 1/4 to 1/2 of lung cancer patients are reported to 
have chronic obstructive pulmonary disease  [15] .
 In the present study, at least 50% of all patients were 
using nonnarcotic analgesics either alone or in combina-
tion with narcotic analgesics. Narcotic analgesic use 
(26.0%) was similar to that in studies by Lester et al.  [5] 
 and Di Maio et al. [14] (19.2 and 23%, respectively); how-
ever, nonnarcotic analgesic use in the current study 
(56.4%) was higher than their results (30 and 13.7%, re-
spectively). Compared to our current data and that from 
previous studies, a study from Greece reported higher use 
of narcotic and nonnarcotic analgesics (80.6 and 64.2%, 
respectively) in cancer patients  [16] . In the current study, 
30.2% of the patients underwent palliative radiotherapy 
for bone metastasis, which is similar to a report by Alexo-
poulos et al.  [16] . Skeletal metastatic disease is the main 
cause of pain and the gold standard treatment for pain 
due to bone metastases is radiotherapy  [17] . Bisphospho-
nates also play an important role in the treatment of bone 
metastasis; however, bisphosphonate use in the current 
study was lower than in the studies by Lester et al. [5] and 
Alexopoulos et al.  [16] .
 The rates for nutritional support in the current study is 
in accordance with several studies reporting variable rates 
between 1.1 and 42.9%  [5, 18] ; however, the use of appetite 
stimulants (e.g., megestrol acetate and cyproheptadine) 
was lower than the percentages of patients with weight 
loss and appetite loss. Appetite stimulants may be effective 
alternatives in cancer patients suffering from anorexia/ca-
chexia syndrome, but their effect on weight gain is contro-
versial  [19–22] . The use of blood products, including 
whole blood, erythrocyte, plasma, etc., was quite common 
in our patients. Erythrocyte and platelet use was reported 
as 9.1% in the LUCEOR study  [5] . While 3.2% of the pa-
tients in that study reported using erythropoiesis-stimu-
lating agents, they were not used at all in the current study.
 The ratio of anxiety and depression in our study 
( ∼ 50%) was comparable to previously reported data  [23] . 
Similar to Salvo et al. [23] we found that female patients 
were more likely to report higher levels of anxiety and 
depression. Again, 48.4% of our patients had sleep prob-
lems, which is similar to Chen at al. [24] and Gooneratne 
et al.  [25] . Sleep quality is associated with the distressing 
symptoms of lung cancer, and studies have shown a clear 
correlation between sleep quality and fatigue  [24, 26] , 
pain  [27] , and dyspnea and cough  [28] . Despite the high 
rates of depression and anxiety in our patients, only 10.6% 
were using anxiolytic/antidepressant treatment. While 
approximately half of our patients had sleep disturbances, 
only 8.5% were using sleeping pills. In contrast to our cur-
rent study, Farriols et al. [28] reported that 84% of pa-
tients were using benzodiazepines and 27.1% were using 
antidepressants, in a general cancer population.
 The most important limitation of this study was that 
data collection was focused on the perceived burden of 
symptoms at a single time point. It is important to ac-
knowledge that the results presented herein reflect only 
one point of a patient’s life, and do not reflect symptoms 
during the entire disease duration.
 Bülbül   et al.
 




 In this study the prevalence of symptoms was higher 
and most severe in patients in the advanced stages of the 
lung cancer than the other stages. Palliative treatment of 
symptoms was mostly inadequate, and large number of 
patients continued to suffer from uncontrolled symp-
toms and unmet needs. Because well-being was clearly 
associated with the distress from the symptoms, control-
ling these symptoms is important in patients with cancer. 
Hence, we recommend that patients undergo regular 
symptom assessment in order to achieve this, and treat-
ment should be provided according to the published 
guidelines. Furthermore, both physician and patient edu-
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